Recursion Pharmaceuticals, Inc. (NASDAQ:
RXRX) is one of the
Best Penny Stocks to Buy with the Highest Upside Potential. On September 10, Gil Blum from Needham reiterated a Buy rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) with a price target of $8.
The analyst noted that the company has formed solid partnerships with major pharmaceutical companies, which are increasingly relying on TechBio companies like Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) for AI and machine learning expertise. He noted that this makes it very important in its field. It is also the only public company with such a significant role.
Moreover, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) chooses to focus on quality partnerships rather than many small deals. These collaborations have the potential for major financial impact. The company is also developing its own platform, RecursionOS, and advancing its internal drug pipeline.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage TechBio company that uses advanced technology to accelerate drug discovery.
While we acknowledge the potential of RXRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the
best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at
Insider Monkey.
